ArticleClinical and experimental medicine2026
The diagnostic and short-term prognostic significance of miR-183-5p in pulmonary embolism and its regulation of disease progression through PDCD4.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of pulmonary thromboembolism (PTE) has increased year on year, with high rates of misdiagnosis and recurrence, as well as significant heterogeneity in prognosis. This study investigated the clinical value of miR-183-5p in PTE, as well as its mechanism of regulating disease progression through PDCD4. This study enrolled 126 PTE patients and 103 non-PTE patients. Serum miR-183-5p was detected using qPCR, and its diagnostic and prognostic significance were analyzed using ROC and logistic analyses. A PTE cell model was established using 150 µg/mL ox-LDL. The effects of inhibiting only miR-183-5p, and co-inhibiting with PDCD4, on the HPMECs functions, inflammation/oxidative stress, and adhesion molecules were analyzed. Serum miR-183-5p in PTE patients increased gradually with risk stratification. The diagnostic efficacy of miR-183-5p for PTE was superior to that of D-dimer, and combining the two provides even better diagnostic results. miR-183-5p was an independent risk factor for prognosis in PTE patients. In a PTE cell model, inhibiting miR-183-5p restored HPMECs proliferation and suppressed apoptosis and autophagy. It also reduced the inflammatory factors release, alleviated oxidative stress damage and down-regulated the adhesion molecules expression. There was a direct target relationship between miR-183-5p and PDCD4. Co-suppression both miR-183-5p and PDCD4 reversed the hindering effect of inhibiting only miR-183-5p on PTE progression. miR-183-5p is a novel biomarker for the supplementary diagnosis and 30-day short-term prognosis assessment of PTE, and it participates in PTE progression by targeting PDCD4 to regulate vascular endothelial cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.